Followers | 507 |
Posts | 10138 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
Saturday, September 12, 2015 1:02:46 PM
bullish
long term
http://ir.nektar.com/
## source: finance.yahoo.com
Thu, 10 Sep 2015 11:03:00 GMT ~ Nektar Therapeutics' Stock Slumped in August; Here's Why
read full: http://www.fool.com/investing/general/2015/09/10/nektar-therapeutics-stock-slumped-in-august-heres.aspx?source=eogyholnk0000001
*********************************************************
Thu, 03 Sep 2015 13:40:01 GMT ~ Nektar Receives $40M Milestone Payment from AstraZeneca
read full: http://finance.yahoo.com/news/nektar-receives-40m-milestone-payment-134001433.html
*********************************************************
Tue, 01 Sep 2015 12:30:00 GMT ~ Nektar Announces Receipt of $40 Million Milestone Payment Resulting from First Commercial Sale of MOVENTIG® (naloxegol) Tablets in Major European Market
[PR Newswire] - SAN FRANCISCO, Sept. 1, 2015 /PRNewswire/ -- Nektar Therapeutics (NKTR) announced today that it has received a $40 million cash payment under a license agreement with AstraZeneca. The payment was triggered by the first commercial sale of MOVENTIG (naloxegol) in Germany. MOVENTIG is the first once-daily, oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication approved in the European Union for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). MOVENTIG is marketed in the U.S. by AstraZeneca as MOVANTIK™ (naloxegol) and is the first once-daily oral PAMORA medication indicated for the treatment of OIC in adult patients with chronic, non-cancer pain.
read full: http://finance.yahoo.com/news/nektar-announces-receipt-40-million-123000224.html
*********************************************************
Fri, 14 Aug 2015 17:04:09 GMT ~ NEKTAR THERAPEUTICS Financials
read full: http://finance.yahoo.com/q/is?s=nktr
*********************************************************
Mon, 10 Aug 2015 00:13:03 GMT ~ 10-Q for Nektar Therapeutics
read full: http://www.companyspotlight.com/routers/headline/23261/10004/6551558?cp_code=YAH1&1439165583
*********************************************************
$NKTR charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$NKTR company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/NKTR/company-info
Ticker: $NKTR
OTC Market Place: Not Available
CIK code: 0000906709
Company name: Nektar Therapeutics
Company website: http://www.nektar.com
Incorporated In: DE, USA
$NKTR share structure
## source: otcmarkets.com
Market Value: $1,620,221,040 a/o Sep 11, 2015
Shares Outstanding: 132,371,000 a/o Jul 30, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$NKTR extra dd links
Company name: Nektar Therapeutics
Company website: http://www.nektar.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NKTR+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NKTR+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NKTR+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/news - http://finance.yahoo.com/q/h?s=NKTR+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NKTR/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NKTR+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NKTR
DTCC (dtcc.com): http://search2.dtcc.com/?q=Nektar+Therapeutics&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Nektar+Therapeutics
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Nektar+Therapeutics&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.nektar.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.nektar.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.nektar.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NKTR
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000906709&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NKTR&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NKTR
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NKTR+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NKTR+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NKTR
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NKTR
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NKTR+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NKTR/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NKTR+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NKTR.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NKTR
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NKTR/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NKTR/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NKTR
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NKTR
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NKTR:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NKTR
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NKTR
$NKTR DD Notes ~ http://www.ddnotesmaker.com/NKTR
Recent NKTR News
- Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets • PR Newswire (US) • 05/02/2024 10:00:00 PM
- Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference • PR Newswire (US) • 03/22/2024 06:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 10:11:03 PM
- Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata • PR Newswire (US) • 03/05/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 09:20:46 PM
- Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results • PR Newswire (US) • 03/04/2024 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 01:40:59 PM
- Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX • PR Newswire (US) • 03/04/2024 01:30:00 PM
- Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference • PR Newswire (US) • 02/27/2024 11:00:00 PM
- Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets • PR Newswire (US) • 02/26/2024 11:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 01:19:39 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 01:17:52 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 01:16:48 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 08:55:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 08:51:14 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 08:50:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 10:16:10 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 10:03:19 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:50:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:25:25 PM
- Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA • PR Newswire (US) • 01/03/2024 11:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 11:07:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 11:05:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 11:05:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/15/2023 05:18:52 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM